Nektar Therapeutics (NKTR) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Nektar Therapeutics is expected to report Q3 2026 results after market close on November 5. Analysts project a loss of $2.07 per share on revenue of $10.27 million; the earnings call is scheduled for November 12 at 5:00 p.m. ET.
• In its latest quarter, Nektar reported a loss of $1.23 per share, beating estimates for a $1.97 loss, while revenue of $10.13 million fell short of expectations. The company continues to post significant losses, with a negative net margin of 287.84%.
• Analyst sentiment is mixed but leans bullish overall: MarketBeat shows a “Moderate Buy” consensus and an average price target of $130.67, despite recent neutral ratings and price-target reductions. Shares opened at $38.55, near the lower end of their 52-week range of $33.40 to $109.00.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nektar Therapeutics to post earnings of ($2.07) per share and revenue of $10.27 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, topping analysts' consensus estimates of ($1.97) by $0.74. The company had revenue of $10.13 million during the quarter, compared to analysts' expectations of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. On average, analysts expect Nektar Therapeutics to post ($8.08) EPS for the current fiscal year and ($11.07) EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock opened at $38.55 on Thursday. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -5.75 and a beta of 1.26. Nektar Therapeutics has a fifty-two week low of $33.40 and a fifty-two week high of $109.00. The stock has a fifty day moving average of $57.14 and a two-hundred day moving average of $64.51.

Insider Buying and Selling

In other news, CEO Howard Robin sold 418 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the transaction, the chief executive officer owned 54,627 shares of the company's stock, valued at $3,932,051.46. This represents a 0.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NKTR shares. UBS Group assumed coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They set a "neutral" rating and a $53.00 price objective on the stock. Wedbush decreased their price target on shares of Nektar Therapeutics from $80.00 to $50.00 and set a "neutral" rating on the stock in a research report on Wednesday, September 23rd. BTIG Research reissued a "buy" rating and set a $178.00 price target on shares of Nektar Therapeutics in a report on Friday, October 9th. Leerink Partners started coverage on shares of Nektar Therapeutics in a research note on Monday, October 12th. They issued an "outperform" rating and a $130.00 target price on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Nektar Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $130.67.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for autoimmune, inflammatory and other serious diseases. The company uses its proprietary biologics and polymer-conjugation technologies to design therapies intended to improve immune-system regulation, drug activity and dosing convenience.

Nektar's pipeline includes rezpegaldesleukin, an investigational treatment designed to expand regulatory T cells and potentially restore immune tolerance in conditions such as atopic dermatitis, alopecia areata and other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.